Want to see TSE:XLY full AI Analyst Report?
XLY Stock Chart & Stats
C$0.18
<C$0.01(2.78%)
At close: 4:00 PM EDT
C$0.18
<C$0.01(2.78%)
Day’s Range― - ―
52-Week RangeC$1.54 - C$3.25
Previous CloseN/A
Volume917.79K
Average Volume (3M)979.68K
Market Cap
C$294.61M
Enterprise ValueC$222.24
Total Cash (Recent Filing)C$43.06M
Total Debt (Recent Filing)C$55.78M
Price to Earnings (P/E)9.3
Beta0.81
Next Earnings
Aug 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.35
Shares Outstanding103,370,320
10 Day Avg. Volume1,296,089
30 Day Avg. Volume979,678
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)1.09
Price to Sales (P/S)1.27
P/FCF Ratio8.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$0.25Price Target Upside38.89% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.14
Revenue Forecast (FY)C$164.50M
Bulls Say, Bears Say
Bulls Say
Revenue Growth MomentumAuxly’s multi-year revenue recovery to C$158.6M TTM and ~22% revenue growth indicate expanding product distribution and market traction in Canada. A sustained top-line uptrend supports scale benefits, better retailer shelf presence, and durable revenue diversification across formats over the next several months.
Strengthened Cash GenerationFirmly positive operating and free cash flow in 2024–TTM and a noted step-up in TTM FCF signal that the business is converting sales into cash. Durable cash generation improves reinvestment capacity, funds working capital and supports debt servicing, reducing structural liquidity risk over the medium term.
Improved Balance Sheet / Lower LeverageMeaningful deleveraging and higher equity have converted prior balance-sheet stress into a more stable capital structure. Reduced leverage and positive returns on shareholder capital in 2025/TTM increase financial flexibility and lower refinancing risk, bolstering durability through industry cycles.
Bears Say
Margin ModerationReported margin compression in the TTM period versus 2025 suggests the pace of profitability improvement is slowing. If pricing pressure, mix shifts toward lower‑margin products, or higher compliance costs persist, margin resilience and the ability to sustain free cash flow gains could be structurally impaired.
Recovery Is RecentThe company’s positive cash generation and earnings are a recent development following several years of negative cash flow. A shorter track record of consistent profitability means the improvements are less battle‑tested through downturns, leaving structural execution and cycle risk higher than long‑established peers.
Regulatory / Channel Concentration RiskAuxly’s business depends on provincial/territorial purchasing and regulated distribution channels and faces excise taxes and compliance burdens. This structural reliance creates persistent demand volatility and margin sensitivity to policy changes or provincial buying decisions, limiting predictability.
Auxly Cannabis Group News
XLY FAQ
What was Auxly Cannabis Group’s price range in the past 12 months?
Auxly Cannabis Group lowest stock price was C$1.54 and its highest was C$3.25 in the past 12 months.
What is Auxly Cannabis Group’s market cap?
Auxly Cannabis Group’s market cap is C$294.61M.
When is Auxly Cannabis Group’s upcoming earnings report date?
Auxly Cannabis Group’s upcoming earnings report date is Aug 13, 2026 which is in 2 days.
How were Auxly Cannabis Group’s earnings last quarter?
Auxly Cannabis Group released its earnings results on May 14, 2026. The company reported C$0 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Auxly Cannabis Group overvalued?
According to Wall Street analysts Auxly Cannabis Group’s price is currently Undervalued.
Does Auxly Cannabis Group pay dividends?
Auxly Cannabis Group does not currently pay dividends.
What is Auxly Cannabis Group’s EPS estimate?
Auxly Cannabis Group’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Auxly Cannabis Group have?
Auxly Cannabis Group has 103,370,320 shares outstanding.
What happened to Auxly Cannabis Group’s price movement after its last earnings report?
Auxly Cannabis Group reported an EPS of C$0 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 7.143%.
Which hedge fund is a major shareholder of Auxly Cannabis Group?
Currently, no hedge funds are holding shares in TSE:XLY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Auxly Cannabis Group Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
C$0.25 (38.89% Upside)
C$0.25 (38.89% Upside)
Insider Transactions
Bought Shares
Worth C$2.0M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
300.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
8.92%
Trailing 12-Months
Company Description
Auxly Cannabis Group
Auxly Cannabis Group Inc. operates as a Canadian consumer packaged goods (CPG) firm focused on the cannabis market. Its primary activities include the development, manufacturing, and distribution of cannabis products, targeting both recreational and wellness consumers. The company offers a wide array of cannabis formats under its distinct brands—KOLAB PROJECT, Dosecann, BACK FORTY, and Foray—including vape cartridges, dried flower, concentrates, chocolates, soft chews, oil drops, capsules, topicals, and hard candy. Originally incorporated in 1987, the company was known as Cannabis Wheaton Income Corp. before officially changing its name to Auxly Cannabis Group Inc. in June 2018. It is headquartered in Toronto, Canada.
XLY Earnings Call
Q1 2026
0:00 / 0:00
XLY Stock 12 Month Forecast
Average Price Target
C$0.25
▲(38.89% Upside)